Featured Press Releases

Prolacta Bioscience Leads in Human Milk Science, Regularly Reviewing Health Claims with FDA

Prolacta Bioscience Leads in Human Milk Science, Regularly Reviewing Health Claims with FDA

A New Production Line Dedicated to Sterile Hyaluronic Acid Has Been Inaugurated by HTL Biotechnology

A New Production Line Dedicated to Sterile Hyaluronic Acid Has Been Inaugurated by HTL Biotechnology

  • 09 Jun 2025

On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high...

Exicure, Inc. (Nasdaq: XCUR) Unveils Next Steps Toward New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. (Nasdaq: XCUR) Unveils Next Steps Toward New Clinical Trial in Acute Myeloid Leukemia (AML)

Fresenius-Kabi_17122024

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

Within one year of its launch, L&C Bio

Within one year of its launch, L&C Bio's 'Re2O' has emerged as a leading procedure in K-Medical Tourism

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

  • Apertura Gene Therapy
  • 28 Apr 2026
AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

  • AbbVie
  • 28 Apr 2026
Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

  • Mundipharma
  • 28 Apr 2026
Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

  • Cellenkos, Inc.
  • 27 Apr 2026
Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

  • Ascletis Pharma Inc.
  • 27 Apr 2026
OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

  • OrthoTrophix, Inc.
  • 26 Apr 2026
The Digital Pharma Advances Conference 2026

Most Popular
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.